A new approach, published in “Cell Reports,” to regenerate inner ear sensory hair cells is said to lay the groundwork for treating chronic noise-induced hearing loss by the company, Frequency Therapeutics, and its co-founders who are drawing on research from Brigham and Women's Hospital (BWH), Harvard Medical School, Mass Eye and Ear Infirmary, and MIT. The program is expected to progress to into human clinical trials within the next 18 months.
The Tubes Under Local Anesthesia (Tula) System is the first ear tube delivery system that can be performed in young children using local anesthesia in a physician’s office setting, according to the FDA's announcement.
Built on the Velox S platform, the new power hearing aid features BrainHearing technology “proven to deliver better speech clarity and better short-term recall while reducing the listening effort people with severe-to-profound hearing loss struggle with in day-to-day listening situations.”
“Our results suggest that tinnitus will likely get louder, but not by very much,” write Hashir Aazh, PhD, and Richard Salvi, PhD, in their recent study published in the Journal of the American Academy of Audiology which shows only a weak association between tinnitus loudness and puretone average (PTA) thresholds.
BlueWing and CounselEAR will collaborate to create customer profiles from CounselEAR’s breadth of client databases, utilizing BlueWing’s data science expertise to facilitate a more intuitive flow of information.
Described as “a transformational sales executive and organizational leader” in Starkey's announcement, Archambault has more than 20 years of experience driving performance and growth in medical device and pharmaceutical organizations.